

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jeffrey T. Blue

Serial No.

Filed:

For: DETECTION OF VIRAL STABILITY

Art Unit: _____

Examiner: _____

Assistant Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

11-9-2001
20455P
11-9-2001
MAILED CV
DATE 11-9-01

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By _____ Date _____

10/030378

JC10 Rec'd PCT/PTO 09 NOV 2001

INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Sheldon O. Heber

By: Sheldon O. Heber

Attorney _____ For Applicant(s)

Reg. No. 38,179

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 1958

Date: 11/9/01

(use as many sheets as necessary)

Sheet

1

of

3

Application Number**Filing Date****First Named Inventor**

Group Art Unit

Examiner Name

Attorney Docket Number

20455P

[illegible][illegible]

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc. 10/05/2001



Substitute for form 1449, PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

COMPLETE IF KNOWN 10/030378

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	1010 Post 1067710	
			Filing Date	09 NOV 2001	
			First Named Inventor	Jeffrey T. Blue	
			Group Art Unit		
			Examiner Name		
Sheet	2	of	3	Attorney Docket Number	20455P

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Thompson, C. B., Apoptosis in the pathogenesis and treatment of disease, Science, Vol 267, pps 1456-1462, 1995.
		Nicholson, D. W., ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis, Nature Biotechnology, Vol 14, pps 297-301, 1996.
		Lincz, L. F., Deciphering the apoptotic pathway: all roads lead to death, Immunology and Cell Biology, Vol 76, pps 1-19, 1998.
		Shen, Y. et al., Viruses and apoptosis, Current Opinion in Genetics and Development, Vol 5, pps 105-111, 1995.
		Sadzot-Delvaux, C. et al., Varicella-zoster virus induces apoptosis in cell culture, Journal of General Virology, Vol 76, pps 2875-2879, 1995.
		Esolen, L. M. et al., Apoptosis as a cause of death in measles virus-infected cells, Journal of Virology, Vol 69, No 6, pps 3955-3958, 1995.
		Ito, M. et al., Detection of measles virus-induced apoptosis of human monocytic cell line (THP-1) by DNA fragmentation ELISA, FEMS Immunology and Medical Microbiology, Vol 15, pps 115-122, 1996.
		Fernandes-Alnemri, T. et al., CPP32, a novel human apoptotic protein with homology to caenorhabditis elegans cell death protein ced-3 and mammalian interleukin-1 beta-converting enzyme, Journal of Biological Chemistry, Vol 269, No 49, pps 30761-30764, 1994.
		Nicholson, D. W. et al., Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis, Nature, Vol 376, pps 37-43, 1995.
		Srinivasula, S. M. et al., The ced-3/interleukin 1 beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2 alpha are substrates for the apoptotic mediator CPP32, Journal of Biological Chemistry, Vol 271, No 43, pps 27099-27106, 1996.
		Schlegel, J. et al., CPP32/apopain is a key interleukin 1 beta converting enzyme-like protease involved in fas-mediated apoptosis, Journal of Biological Chemistry, Vol 271, No 4, pps 1841-1844, 1996.
		Casciola-Rosen, L. et al., Apopain/CPP32 cleaves proteins that are essential for cellular repair: a fundamental principle of apoptotic death, J. Exp. Med., Vol 183, pps 1957-1964, 1996.
		Fernandes-Alnemri, T. et al., Mch3, a novel human apoptotic cysteine protease highly related to CPP32, Cancer Research, Vol 55, pps 6045-6052, 1995.
		Zhang, G. et al., Detection of caspase activity associated with apoptosis using fluorimetric and colorimetric methods, Apoptosis Detection and Assay Methods, pps 7-14, 1998.
		ApoAlert Caspase-3 Assay Kits User Manual, PT3083-1, CLONTECH Innovative Tools to Accelerate Discovery, pps 1-11, 1999.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered.
 Include copy of this form with next communication to applicant.

(use as many sheets as necessary)

Sheet

3

of

3

Application Number**Filing Date****First Named Inventor**

Group Art Unit

Examiner Name

Attorney Docket Number

20455P

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Villa, P. et al., Caspases and caspase inhibitors, TIBS, Vol 22, pps 388-393, 1997.

Hockenbery, D., Defining Apoptosis, American Journal of Pathology, Vol 146, No 1, pps 16-18, 1995.

Lazebnik, Y. A. et al., Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE, *Nature*, Vol 371, pps 346-347, 1994.

Yuan, J. et al., The *C. elegans* cell death gene *ced-3* encodes a protein similar to mammalian interleukin-1 β -converting enzyme, *Cell*, Vol 75, pps 641-652, 1993.

ApoAlert CPP32 protease assay kits, CLONTECHniques, pps 4-6, 1997.

Examiner
Signature

Date
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.